GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Cancer Science

Volumn 98, Issue 10, 2007, Pages 1625-1632

  Noguchi, Mariko ^a,b   Suzuki, Tomoko ^a   Kabayama, Kazuya ^b,h   Takahashi, Hiroki ^c   Chiba, Hirofumi ^c   Shiratori, Masanori ^c   Abe, Shosaku ^c   Watanabe, Atsushi ^d   Satoh, Masaaki ^e   Hasegawa, Tadashi ^d   Tagami, Seiichi ^f   Ishii, Atsushi ^a   Saitoh, Masaki ^g   Kaneko, Masanori ^a   Iseki, Ken ^a   Igarashi, Yasuyuki ^a   Inokuchi, Jin Ichi ^b,h  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c School of Medicine   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Sapporo Medical Center   (Japan)

^f Iwamizawa Rousai Hospital   (Japan)

^g MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^h JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GANGLIOSIDE GM3; GANGLIOSIDE GM3 SYNTHASE; GEFITINIB; MEMBRANE ENZYME; MESSENGER RNA; MUCIN; PROTEIN SAT 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL CLONE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IC 50; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; G(M3) GANGLIOSIDE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MICE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIALYLTRANSFERASES; TUMOR CELLS, CULTURED;

EID: 34548146344     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00578.x     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol 2005; 5: 343-9.
3. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003; 22: 179-81.
4. Inoue A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-9.
5. Okamoto I, Fujii K, Matsumoto M et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003; 40: 339-42.
6. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) 'corrected'. J Clin Oncol 2003; 21: 2237-46.
7. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-26.
8. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-58.
9. Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-9.
10. Nishiwaki Y, Yano S, Tamura T et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib. Gan Kagaku Ryoho 2004; 31: 567-73.
11. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
12. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
13. Hakomori S. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. J Biol Chem 1990; 265: 18 713-16.
14. Miljan EA, Bremer EG. Regulation of growth factor receptors by gangliosides. Sci STKE 2002; 2002: RE15.
15. Uemura S, Kabayama K, Noguchi M, Igarashi Y, Inokuchi J. Sialylation and sulfation of lactosylceramide distinctly regulate anchorage-independent growth, apoptosis, and gene expression in 3LL Lewis lung carcinoma cells. Glycobiology 2003; 13: 207-16.
16. Noguchi M, Kabayama K, Uemura S et al. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells. Glycobiology 2006; 16: 641-50.
17. Taki T, Handa S, Ishikawa D. Blotting of glycolipids and phospholipids from a high-performance thin-layer chromatogram to a polyvinylidene difluoride membrane. Anal Biochem 1994; 221: 312-16.
18. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-57.
19. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-15.
20. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 2006; 42: 17-23.
21. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors - the bull's-eye hits the arrow. Cancer Cell 2004; 5: 411-15.
22. Miljan EA, Meuillet EJ, Mania-Farnell B et al. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem 2002; 277: 10 108-13.
23. Wang XQ, Sun P, Paller AS. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J Biol Chem 2003; 278: 48 770-8.
24. Wang XQ, Sun P, Paller AS. Ganglioside induces caveolin-1 redistribution and interaction with the epidermal growth factor receptor. J Biol Chem 2002; 277: 47 028-34.